Compare Abbott Laboratories (ABT) vs Nvidia Corp (NVDA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Nvidia Corp — how do they compare? Abbott Laboratories trades at $95.8 (market cap $166.94B), while Nvidia Corp trades at $199.52 (market cap $4.77T). The key difference: Nvidia Corp is far larger — about 28.6× Abbott Laboratories's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | NVDA | |
|---|---|---|
Market Cap | $166.94B | $4.77T |
Sector | Health | Technology |
52-Week High | $136.62 | $235.75 |
52-Week Low | $82.57 | $160.00 |
Enterprise Value | $193.69B | $4.70T |
Dividend Yield | 2.63% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
NVIDIA (NVDA) trades at $197.62, up 1.06% on the day, with technical indicators showing a bearish bias despite recent earnings beats. The company demonstrates exceptional fundamental strength with revenue surging to $130.5B in 2025 and net profit margins expanding to 55.84%. Analyst consensus remains strongly bullish with a $324.95 price target, representing significant upside potential from current levels.
NVIDIA's outlook is supported by dominant AI chip positioning and accelerating revenue growth, though risks include increased competition, peak AI infrastructure spending concerns, and rich valuations. The stock presents a compelling growth opportunity for investors comfortable with technology sector volatility and premium valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
